Clinical Trials for Anemia

120 anemia trials indexed, 46 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding Anemia

Anemia is a medical condition where the body does not have enough healthy red blood cells or hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen to the body's tissues. When hemoglobin levels are low, the body’s organs and tissues do not get enough oxygen, which can cause fatigue and other symptoms. Anemia can result from various causes, including blood loss, decreased red blood cell production, or increased destruction of red blood cells. Doctors diagnose anemia using blood tests, primarily by measuring hemoglobin concentration and hematocrit levels. A hemoglobin level below 13.5 grams per deciliter in men and 12.0 grams per deciliter in women typically indicates anemia.

Common symptoms of anemia include weakness, tiredness, pale or yellowish skin, shortness of breath, dizziness, and cold hands and feet. The condition can affect people of all ages but is more common in certain groups. Older adults and women of childbearing age are more likely to develop anemia. Women may experience anemia due to menstrual blood loss or pregnancy. Other risk factors include nutritional deficiencies (such as iron, vitamin B12, or folate), chronic diseases like kidney disease or cancer, and inherited conditions such as sickle cell anemia or thalassemia. Anemia can also develop in people with chronic infections or inflammation.

Anemia matters both medically and socially because it affects a large portion of the population and can reduce quality of life. According to the World Health Organization, anemia affects about 24.8% of the global population. It is particularly common in low-income countries and among children and pregnant women. Anemia can lead to serious health complications, including increased risk of heart problems and delayed development in children. Economically, anemia contributes to lost productivity and increased healthcare costs. For example, iron deficiency anemia alone accounts for billions of dollars in lost workdays worldwide each year. Understanding and managing anemia is important to reduce its widespread impact.

The Anemia Treatment Landscape

The first-line treatment for anemia depends on the underlying cause but often starts with addressing nutritional deficiencies. Iron deficiency anemia, the most common type, is usually treated with oral iron supplements. These supplements help restore iron levels necessary for red blood cell production. If oral iron is not effective or not tolerated, intravenous iron may be used. For anemia caused by vitamin B12 or folate deficiency, supplementation of these vitamins is the standard approach. In cases where anemia is due to chronic disease or blood loss, treating the underlying condition is a priority. Blood transfusions may be used in severe cases to quickly increase red blood cell counts.

When first-line treatments are not sufficient or appropriate, second- and third-line options come into play. These can include erythropoiesis-stimulating agents (ESAs), which stimulate the bone marrow to produce more red blood cells. ESAs are commonly used in anemia related to chronic kidney disease or chemotherapy. Other drug classes under study or in use target specific causes, such as immunosuppressants for autoimmune hemolytic anemia. In rare cases, bone marrow transplantation may be considered for inherited or severe refractory anemia. The choice of treatment depends on the type and severity of anemia, as well as patient-specific factors.

Despite available treatments, there are still gaps in managing anemia effectively. Some patients do not respond well to oral iron due to absorption issues or side effects like gastrointestinal discomfort. Others may develop resistance to ESAs or experience serious side effects, including increased risk of blood clots. Certain subgroups, such as those with anemia of chronic disease or bone marrow failure syndromes, have limited treatment options. Research is ongoing to develop new therapies that are safer and more effective. Clinical trials are focusing on drugs that target the underlying causes of anemia and ways to improve delivery and tolerance of existing treatments.

Why Clinical Trials Matter for Anemia

Clinical trials offer patients access to new treatments that are not yet widely available. For people with anemia, participating in a trial can mean closer medical monitoring and the chance to try therapies that might better control their condition. According to ClinicalTrials.gov, there are currently about 120 clinical trials focused on anemia. Of these, 46 are actively recruiting participants. These trials cover a range of anemia types and treatment approaches. By joining a trial, patients contribute to scientific knowledge that may help improve care for others with anemia in the future.

There are risks involved in participating in clinical trials. New treatments may not work as expected or could cause side effects that are not yet fully understood. Some trials include placebo groups, meaning some participants may not receive the experimental treatment. Additional clinic visits, tests, and procedures are often required, which can be time-consuming and inconvenient. Patients should carefully consider these factors and discuss them with their healthcare providers before enrolling in a trial. Understanding both the potential benefits and risks helps ensure informed decisions.

The landscape of anemia clinical trials includes studies sponsored by academic institutions, pharmaceutical companies, and cooperative research groups. Academic centers often focus on understanding disease mechanisms and testing new scientific approaches. Industry sponsors typically develop and test new drugs or devices. Cooperative groups bring together multiple centers to conduct large-scale trials. ClinicalTrials.gov serves as a central registry that lists these studies, providing transparency and helping patients and doctors find trials that match specific needs. This registry is an important resource for anyone interested in exploring clinical trial options for anemia.

What to Look for in a Anemia Clinical Trial

Clinical trials are divided into four main phases. Phase 1 trials test a new treatment in a small group to evaluate safety and dosage. Phase 2 trials focus on effectiveness and side effects in a larger group. Phase 3 trials compare the new treatment to current standard treatments in an even larger group. Phase 4 occurs after approval, monitoring long-term effects. For anemia, the most common phase is Phase 2, with 27 trials. There are 20 trials each in Phase 3, Phase 1, and 20 with no phase assigned. This distribution helps patients understand the stage of research they might join.

Inclusion criteria for anemia trials often depend on factors like age, previous treatments, and specific blood markers. Many trials require adults within a certain age range, such as 18 to 65 years. Some focus on patients who have not responded well to standard anemia treatments. Biomarkers like hemoglobin levels or iron studies may be used to select participants. Disease duration and severity also matter; some trials look for newly diagnosed patients, while others include those with chronic anemia.

Exclusion criteria help protect patient safety and ensure clear results. Patients with other serious health conditions may be excluded to avoid complications. For example, people with heart or kidney disease might not qualify if these conditions could interfere with the trial treatment. Drug interactions are another concern, so patients taking certain medications may be excluded. Safety thresholds, such as minimum blood counts or organ function levels, are set to reduce risks during the study.

When considering a trial, practical details are important. The length of the trial can range from a few weeks to several months or longer. Visit schedules vary; some trials require frequent hospital visits, while others may have fewer appointments. Travel distance and costs should be factored in. Patients should ask the research team key questions: What are the possible side effects? How often will I need to visit the clinic? What happens if I want to leave the trial early? Will my regular doctor be informed about my participation?

Primary Sources and Further Reading

For patients and caregivers seeking more information about anemia and clinical trials, trusted sources provide detailed and reliable content. These websites offer guidance on anemia symptoms, treatments, and ongoing research. They also explain how clinical trials work and how to find one that fits your needs.

Latest Research and Emerging Treatments for Anemia (2026)

Recent anemia research focuses on new drugs and therapies that could improve treatment options for patients. One example is ferumoxytol, an intravenous iron formulation being tested against iron sucrose in children with iron deficiency anemia (NCT03893045). Both drugs supply iron, which is essential for making healthy red blood cells. Ferumoxytol may offer a different dosing schedule or fewer side effects, which could make anemia treatment easier for pediatric patients and their families.

Gene-editing therapies like CTX001 are also under study for conditions such as beta-thalassemia and sickle cell disease (NCT04208529, NCT05477563). These treatments aim to modify a patient’s own stem cells to produce healthier red blood cells, potentially reducing or eliminating the need for frequent blood transfusions. If successful, this approach could improve quality of life by lowering treatment burdens and associated risks.

For anemia related to chronic kidney disease, oral medications like roxadustat are being tested in children and teenagers (NCT05970172). Roxadustat works by stimulating the body’s natural response to low oxygen levels, encouraging red blood cell production without injections. This new anemia treatment 2026 could offer a more convenient option compared to current therapies that often require regular injections. Another study compares MT-6548 with darbepoetin alfa, a common anemia drug, to see if it provides similar or better results with manageable safety (NCT03329196). These trials reflect ongoing efforts to find anemia treatments that fit patient needs and lifestyles better.

Frequently asked questions about Anemia trials

How do I find Anemia clinical trials?

The authoritative source for Anemia clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 120 anemia studies are currently indexed. You can search by entering "anemia" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new anemia trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most Anemia trials in?

Across the 120 anemia trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many Anemia clinical trials are currently recruiting?

As of the latest scan, 46 anemia trials have a "Recruiting" status on ClinicalTrials.gov, out of 120 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting anemia trial matches their tracked condition.

Stay informed about anemia research

Get a weekly briefing with the trials that matter most.

Start monitoring anemia trials